Aesthetics practices and medical directors face significant exposure under both federal DSCSA requirements and state board enforcement. If your practice purchases, stores, or administers any Rx product — neurotoxins, fillers, GLP-1s, peptides — you are in scope. State boards in New York, Ohio, and California are actively co-enforcing with shared FDA inspection data.

Biologics, injectables, and specialty Rx products are fully in scope. Missing lot tracking and vendor documentation are the most common findings.

Chemotherapy, immunotherapy, and biologic infusions carry the highest DSCSA exposure. Complete transaction documentation required at every custody transfer.

Anti-VEGF agents such as Eylea, Lucentis, and Avastin are prescription drug products that move through the regulated pharmaceutical supply chain. That makes them fully subject to DSCSA requirements, regardless of the fact that they are administered in-office rather than dispensed to a patient to take home. The same applies to other in-office administered agents topical anesthetics, dilating drops, anti-infectives, and cosmetic injectables — when purchased as finished, manufacturer-produced prescription drug products.

In-office biologic infusions are a primary enforcement target. Specialty pharmacy sourcing creates documentation inconsistencies inspectors flag immediately.

Vaccines, injectables, and any in-office Rx product are in scope. Most primary care operators assume DSCSA applies only to pharmacies. That assumption is now demonstrably wrong.

High-value products administered at volume without hospital compliance infrastructure creates significant exposure.

Buy-and-bill purchasing creates specific traceability requirements. Luteinizing hormone agents and in-office oncology treatments require full transaction documentation.

MS infusion agents, therapeutic botulinum toxin, and CGRP antagonists administered in-office all require complete authorized distributor documentation.